Dispatch Bio is building a system that could broaden treatment for a wide variety of tumors, and it’s about to start testing ...
PHILADELPHIA.Today on MSN
Penn spinout Dispatch Bio moves virus-based cancer treatment to human trials
A University City biotech founded just three years ago is about to test whether a virus can outsmart cancer’s biggest defense, reports Sarah Huffman for Technical.ly. Dispatch Bio is preparing to move ...
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
PHILADELPHIA & SAN FRANCISCO, January 12, 2026--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This three-year-old company is ...
Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the presentation of new preclinical data supporting ...
First-in-class Flare platform designed to address targeting and resistance mechanisms in solid tumors to expand curative potential of immunotherapies for cancer patients Platform based on convergence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results